A comparison of overall survival with brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi) Meeting Abstract
| Authors: | Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K. M.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; Stilgenbauer, S.; Thieblemont, C.; Lambert, J.; Zilioli, V. R.; Sancho, J. M.; Jimenez-Ubieto, A.; Fischer, L.; Eyre, T. A.; Keeping, S.; Park, J. E.; Wu, J. J.; Siddiqi, R.; Reitan, J.; Castaigne, G.; Salles, G. |
| Abstract Title: | A comparison of overall survival with brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 10296 |
| End Page: | 10299 |
| Language: | English |
| ACCESSION: | WOS:000893230303139 |
| DOI: | 10.1182/blood-2022-162638 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
